Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:1390:227-239.
doi: 10.1007/978-3-031-11836-4_13.

Genomic Insights into Non-steroidal Nuclear Receptors in Prostate and Breast Cancer

Sajad A Wani  1 , Moray J Campbell  2
Affiliations

Genomic Insights into Non-steroidal Nuclear Receptors in Prostate and Breast Cancer

Sajad A Wani et al. Adv Exp Med Biol. 2022.

Abstract

Alterations in transcriptional programs are a fundamental feature of prostate (PCa) and breast cancer (BrCa), and frequently target the actions of the principal steroidal nuclear receptors (NRs), namely the androgen receptor (AR) and the estrogen receptor alpha (ERα), respectively. Indeed, the functions of AR and ERα are central to both prostate and mammary gland biology. The genomic interactions of these NRs become highly distorted in part by changing how they functionally interact with a cohort of non-steroidal Type II NRs, which are by contrast relatively understudied compared to their steroidal cousins. For example, the AR cistrome overlaps with cistromes of different Type II NRs, which suggests a high potential for integrated NR functions to tailor transcriptional signals. Over recent years the cistromes of these Type II NRs, including HNF4s, RARs, PPARs and VDR, have been studied in PCa and BrCa revealing convergence and functional consequences, and are reviewed in the current chapter.

Keywords: Bookmarking; Breast cancer; Cistrome; Epigenetics; Non-steroidal nuclear receptors; Prostate cancer; Transcriptome.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. De Bosscher K, Desmet SJ, Clarisse D, Estebanez-Perpina E, Brunsveld L (2020) Nuclear receptor crosstalk – defining the mechanisms for therapeutic innovation. Nat Rev Endocrinol 16:363–377 - PubMed - DOI
    1. Zhao L, Zhou S, Gustafsson JA (2019) Nuclear receptors: recent drug discovery for cancer therapies. Endocr Rev 40:1207–1249 - PubMed
    1. Long MD, Campbell MJ (2015) Pan-cancer analyses of the nuclear receptor superfamily. Nucl Receptor Res 2
    1. Duez H, Staels B (2010) Nuclear receptors linking circadian rhythms and cardiometabolic control. Arterioscler Thromb Vasc Biol 30:1529–1534 - PubMed - PMC - DOI
    1. Sonoda J, Pei L, Evans RM (2008) Nuclear receptors: decoding metabolic disease. FEBS Lett 582:2–9 - PubMed - DOI

Substances

LinkOut - more resources